Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07755020 | Nitride-Based Raman Biochip for Lung Cancer Diagnosis and Monitoring | recruiting | — | 3,000 | Taichung Veterans General HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06515990 | A Study of DM005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Doma Biopharmaceutical（Suzhou）Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07751783 | Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations | recruiting | N/A | 150 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04151940 | PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer | recruiting | N/A | 80 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05401110 | Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer | recruiting | Phase 1 | 60 | Karen Reckamp, MD, MSOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05995821 | Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies | recruiting | — | 1,250 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT06634056 | Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation(P4-PACIFIC) | recruiting | Phase 2 | 150 | University Health Network, TorontoOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | recruiting | Phase 1 | 30 | University of PennsylvaniaOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04999761 | AB122 Platform Study | recruiting | Phase 1 | 917 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06449313 | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features(NEO-SURG) | recruiting | Phase 2 | 21 | Georgetown UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06473961 | A Phase Ib Study of GC101 in NSCLC(MIZAR-005) | recruiting | Phase 1 | 20 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06706076 | A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations(SOLARA) | recruiting | Phase 1 / Phase 2 | 675 | BlossomHill TherapeuticsINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07111520 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 1 / Phase 2 | 880 | BioNTech SEINDUSTRY | 10 | Aug 5, 2026 | clinicaltrials |
| NCT07412041 | Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study(PERCC) | recruiting | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07560111 | A Phase II Study of GC101 in NSCLC | recruiting | Phase 2 | 28 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07746323 | Effect of Modified Arm Positioning on Shoulder Pain After Thoracoscopic Lobectomy | recruiting | N/A | 270 | Chengdu Jinjiang Maternity and Child Health HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748325 | Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC(RICA) | recruiting | Phase 2 | 100 | Sichuan UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT01639508 | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | recruiting | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT06199570 | Support for Cancer Patients Awaiting News(SCAN) | recruiting | N/A | 60 | Hackensack Meridian HealthOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06923774 | European Real-World Registry for Use of the Ion Endoluminal System | recruiting | — | 1,200 | Intuitive SurgicalINDUSTRY | 4 | Aug 4, 2026 | clinicaltrials |
| NCT07545954 | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744256 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)(PULSE) | recruiting | Phase 4 | 107 | Anhui Provincial Cancer HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06215326 | Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients(PRE-EXELUCA) | recruiting | N/A | 100 | Guangdong Provincial People's HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 370 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07642024 | A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) | recruiting | Phase 2 / Phase 3 | 90 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741435 | Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia(METHYLSCAPE-CO) | recruiting | — | 3,250 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07742332 | Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC | recruiting | Phase 2 | 160 | Peng ZhangOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07743021 | Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data(H4H) | recruiting | — | 15,000 | Center for Molecular Fingerprinting Research Nonprofit LLCOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06433206 | Care Needs in Lung Cancer Patients Receiving Immunotherapy | recruiting | — | 180 | National Taiwan University HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07402343 | Tarlatamab for SCLC Brain Metastases(T-BRAIN) | recruiting | Phase 2 | 35 | Maastricht University Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07646847 | A Study of a Side Effects and Resource Navigation Program for People With Cancer | recruiting | N/A | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739121 | Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations(BEACON) | recruiting | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07740239 | A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial(COSMOS-I) | recruiting | — | 2,050 | Tampere University HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06410300 | Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy | recruiting | — | 125 | Bo LuOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06540196 | The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer(NodeAI) | recruiting | N/A | 600 | McMaster UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05632809 | REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) | recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT07008664 | Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer | recruiting | — | 750 | University of Maryland, BaltimoreOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07623356 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 265 | AkesoINDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05950139 | Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC(ARCHER) | recruiting | Phase 1 / Phase 2 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 10, 2026source: clinicaltrials